Get the latest Science News and Discoveries

New evidence shows tirzepatide and semaglutide strongly protect the heart


A massive real-world study comparing tirzepatide and semaglutide reveals both drugs deliver strong, early cardiovascular protection—reducing heart attack, stroke, and death in adults with type 2 diabetes. While companies have claimed large differences favoring their own medications, researchers found only modest distinctions between the two blockbuster GLP-1 drugs.

None

Get the Android app

Or read this on ScienceDaily

Read more on:

Photo of Semaglutide

Semaglutide

Photo of heart

heart

Photo of new evidence

new evidence

Related news:

News photo

Nationwide awards honor local students and school leaders championing heart, brain health - EurekAlert!

News photo

AI at the heart of new SFU gel-free ECG system for faster diagnoses - EurekAlert!

News photo

New 'heart percentile' calculator helps young adults grasp their long-term risk - EurekAlert!